Posaconazole prophylaxis during antithymocyte gloulin (ATG) treatment for hypoplastic myelodysplastic syndrome (hMDS)/ aplastic anemia (AA) patients

Seoul National University Hospital0 个研究点目标入组 40 人开始时间: 待定最近更新: 2019年4月23日

概览

暂无简介。

•? An adult patient diagnosed with aplastic anemia or hypoplastic myelodysplastic syndrome is treated with antithymocyte globulin.
•? Those who can express their willingness to participate in clinical trials.
•? Adult patients aged more than 18 and under 75 years old.
•? Person without corrected QT interval(the time between the start of the Q wave and the end of the T wave) prolongation in electrocardiogram.
•? Those who have no problem with each organ function and meet the criteria below:
•A. Serum creatinine \= 2\.0 times upper limit of normal
•B. Serum bilirubin \= 1\.5 times upper limit of normal
•C. Aspartate transaminase and alanine transaminase \= 2\.0 times upper limit of normal

•? Patients suspected of fungal infection within 30 days of treatment of antithymocyte globulin
•? Someone who was allergic to \-triazols drug
•? Someone with a history of other cancers in five years.
•? Anti\-cancer, radiation\-treated person
•? Current breastfeeding or pregnant female, all patients without birth control plan
•? Patient with current active hepatitis B or C
•? Patient who is positive for human immunodeficiency virus.
•? A transplant patient
•? Person with corrected QT interval(the time between the start of the Q wave and the end of the T wave) prolongation in baseline electrocardiogram or patients with Torsades de pointes.
•? Patients taking the following medications \- ergotamine alkaloid, cytochrome P450 3A4 substrate terfenadine, astemizole, cisapride, pimozide, halofantrine, quinidine, or hydroxymethylglutaryl coenzyme A reductase inhibitor.

发起方